Emergency EEG maker Ceribell raises $35M in series B round

The system's headband includes a “brain stethoscope” feature that converts EEG signals to sound. (Image: Whipsaw)

Ceribell raised $35 million to fund commercialization of its rapid response EEG system, which can quickly diagnose patients suspected of having nonconvulsive seizures with no visual symptoms, for use in neurological intensive care units and emergency rooms.

The Mountain View, California-based company’s platform, which received 510(k) clearance from the FDA in 2017, is designed to diagnose patients within six minutes, compared to typical EEGs that may take hours or days, according to Ceribell.

The system consists of a disposable headband and cloud-based mobile recording device, allowing a specialist to review the patient’s EEG remotely. It also includes a “brain stethoscope” feature that converts EEG signals to sound.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

The series B round was led by Optimas Capital Partners Fund and The Rise Fund, which is managed by TPG Growth, plus funding from the pharma company UCB and medtech developer LivaNova.

“Ceribell’s unique approach combining user-centric design, AI data analytics and digital health has the potential to revolutionize how clinicians monitor for seizures and minimize the time from seizure onset to treatment,” said Heath Lukatch, partner at TPG.

“This platform can not only have a significant positive impact on the health and treatment of patients in the United States, but also more broadly across the world where EEG and trained neurologists are not available,” Lukatch added.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.